Despite prior meta-analyses indicating that roxadustat could improve Hb levels and is typically tolerated fairly well in DD-CKD patients, the proof among individuals undergoing HD with CKD remains inadequate [16,17]. Here, GSTM1 is linked to chronic kidney disease.